)
Visual24 Oct 2025
The rise of Alphabet
Microbix Biosystems (MBX) investor relations material
Microbix Biosystems Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Aug, 2025
Executive summary
Q3 2025 revenue dropped to $3.5M, the lowest in 11 quarters, due to reduced Chinese demand and a major QAPS client halting development, resulting in a net loss of $1.64M for the quarter and $0.77M YTD loss.
Customer concentration risk materialized, with simultaneous slowdowns from both clients impacting revenue and margins.
Gross margin fell to 41% in Q3 from 54% last year, with YTD gross margin at 56% versus 63% in YTD 2024.
Despite setbacks, recurring sales remained stable year-over-year, and growth continues in other client segments.
Management remains focused on resuming growth, diversifying the customer base, and launching new products and strategic initiatives, including onboarding recombinant antigen capabilities and expanding QAPS.
Financial highlights
Q3 2025 revenue: $3.47M, down 31% from Q3 2024; YTD revenue: $14.84M, down 22% year-over-year.
Q3 net loss: $1.64M vs. net income of $0.25M in Q3 2024; YTD net loss: $0.77M vs. net income of $3.08M in YTD 2024.
Excluding the two affected clients, year-to-date growth was 13% in the caps business and 34% in antigens.
Margins were negatively impacted by lower sales volumes, unfavorable product mix, and fixed manufacturing costs.
Cash and cash equivalents stood at $12.1M, with a current ratio of 9.73 and debt-to-equity ratio of 0.3.
Outlook and guidance
At least one more challenging quarter is expected before recurring sales recover; management expects it will take several quarters to return to targeted growth and profitability.
QAPS segment expected to be the fastest-growing revenue source through fiscal 2027, driven by new products, regulatory changes, and PoCT adoption.
Revenue growth targeted via recombinant antigens, QAPS expansion, and Kinlytic milestone/royalty payments.
Cautious optimism for a recovery in Asian antigen sales in the fall/winter 2025-26 season, depending on disease prevalence.
Management aims to achieve higher and more consistent sales volumes, expand gross margins, and drive net earnings and free cash flow.
Assess timeline for antigen business recovery in Asia.
Elaborate on the Kinlytic royalty agreement structure.
Detail QUANTDx market size and Microbix's target share.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Microbix Biosystems earnings date
Q4 202518 Dec, 2025
Next Microbix Biosystems earnings date
Q4 202518 Dec, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Microbix Biosystems Inc. is a life sciences company that develops and commercializes a range of proprietary biological and technological solutions aimed at improving human health and wellbeing. The company, established in 1988, has a focus on the global diagnostics industry, producing high-quality biological materials. These include antigens used in immunoassays and various Quality Assessment and Proficiency (QAPs) testing products. Microbix Biosystems also manufactures diagnostic-test products, including test-controls under the QAPs brand and viral transport mediums used for collecting patient samples. Additionally, the company is involved in the development of Kinlytic, a biologic thrombolytic drug for treating blood clots. The company is headquartered in Mississauga, Ontario, Canada, and its shares are listed on the Toronto Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage